Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPPING: Maintenance Pazopanib vs Placebo in NSCLC After First-line Chemotherapy
2010-018566-23Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Maintenance pazopanib with Placebo control (2 arms). Primary endpoint: overall survival. Started Jan 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-018566-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018566-23.